New radioactive drug targets prostate cancer in early trial
NCT ID NCT06641219
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small, completed Phase 1 study tested a single injection of a radioactive drug called Lutetium-177 BQ7876 in 7 men with prostate cancer. The main goals were to see how the drug spreads in the body, how much radiation reaches tumors, and whether it is safe. Because it is very early research, the results will only show if the drug behaves as expected, not if it can treat the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutetium-177 labeled BQ7876 (a radioactive drug)
What this could lead to
If successful, this could lead to a new targeted radiation therapy for prostate cancer that delivers radiation directly to cancer cells.
What could go wrong
This is a very early Phase 1 study with only 7 participants, so it is too small to prove effectiveness. The drug may not work as hoped or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
TomskNRMC
Tomsk, 634050, Russia